Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety of Carbergoline Versus Placebo for Antipsychotic Induced Hyperprolactinemia: A Pragmatic, Randomised, Non-inferiority Trial With Blinded Outcome.

NCT07386080 is registered in ClinicalTrials.gov with Zealand University Hospital as lead sponsor.

NCT NCT07386080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07386080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety of Carbergoline Versus Placebo for Antipsychotic Induced Hyperprolactinemia: A Pragmatic, Randomised, Non-inferiority Trial With Blinded Outcome.
Lead sponsor
Zealand University Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
May 1, 2029
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

scizophrenia